Side-by-side · Research reference
AdipotidevsDermorphin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED15/49 cited
BAnimal-StrongHUMAN-REVIEWED20/47 cited
Adipotide
Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only
IV · Systemic · Preclinical Protocols OnlyHossen 2013
Dermorphin
Opioid Peptide · μ-Receptor Agonist · Research Only
Research only · ICV / SC (animal models)
01Mechanism of Action
Parameter
Adipotide
Dermorphin
Primary target
Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013
μ-opioid receptors (central and peripheral)Negri 1992Steel 2014
Pathway
CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption
μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization
Downstream effect
Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss
Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects
Feedback intact?
N/A — Direct apoptotic mechanism, non-hormonal
N/A — exogenous opioid agonist
Origin
Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence
Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998Mignogna 1992
02Dosage Protocols
Parameter
Adipotide
Dermorphin
Animal dose (mouse)
Low dose (not specified in abstract)Hossen 2013
Systemic injection in diet-induced obesity (DIO) models.Hossen 2013
—
Route
Intravenous (systemic injection)
—
Frequency
Not specified in available data
—
Evidence basis
Preclinical animal models only
Animal studies · In vitro assays
Human data
None — no clinical trials reported
—
Legal status
—
Controlled substance in many jurisdictions · Research only
Not approved for human use.
Animal research (ICV)
—
Low nanomolar to picomolar range
Intracerebroventricular administration in rodent models.
Detection limit (doping)
—
5 pg/mL in equine plasma/urineSteel 2014
High-throughput LC-MS/MS screen developed for racing industry.
Duration of action
—
10–120 minutes (dose-dependent, intrathecal)
Human toxicity
—
Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025
03Metabolic / Fat Loss Evidence
Parameter
Adipotide
Dermorphin
Primary fat target
White adipose tissue (all depots)
—
Body weight reduction
Significant reduction in DIO miceHossen 2013
Absolute values not provided in abstract.
—
Leptin levels
Significant decrease
Parallel to adipose mass reduction.
—
Effect on adipocytes
Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013
—
Ectopic fat
Reduction in ectopic fat depositionHossen 2013
Marker of dysfunctional adipose tissue / metabolic syndrome.
—
Species tested
Obese rhesus monkeys, DIO mice
—
Human translation
Unknown — no clinical trials
—
04Side Effects & Safety
Parameter
Adipotide
Dermorphin
Safety profile
Unknown — preclinical data only
—
Vascular selectivity
Targets adipose vasculature; off-target vascular effects unknown
—
Apoptotic mechanism risk
Pro-apoptotic payload may affect unintended tissues if selectivity incomplete
—
Kidney / liver toxicity
Not reported in available data
—
Immunogenicity
Not assessed in available data
—
Opioid effects
—
Respiratory depression, sedation, euphoria, tolerance, dependence risk
Kambô ritual toxicity
—
Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025
Receptor selectivity caveat
—
Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992
Proteolytic stability
—
Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996
Absolute Contraindications
Adipotide
- ·Human use — not approved, no clinical safety data
Dermorphin
- ·Human use — not approved by any regulatory authority
- ·Controlled substance status — possession illegal in many jurisdictions
- ·Known opioid hypersensitivity or respiratory compromise
Relative Contraindications
Adipotide
- ·Any condition requiring intact adipose-tissue vascularisation
Dermorphin
- ·Any context outside approved animal research protocols
- ·CNS depressant co-administration
05Administration Protocol
Parameter
Adipotide
Dermorphin
1. Route
Intravenous injection (systemic) in preclinical models. No human protocols exist.
Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.
2. Formulation
Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013
In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.
3. Preclinical dosing
Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013
High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014
4. Storage
Not specified — likely requires peptide-grade lyophilised storage and reconstitution.
Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025